Cytokinetics (CYTK) announced its intention to offer, subject to market conditions and other factors, $550M aggregate principal amount of convertible senior notes due 2031 in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYTK:
- Cytokinetics’ COMET-HF Study: A Potential Game-Changer for Heart Failure Treatment?
- Cytokinetics’ Aficamten Study: A Potential Breakthrough for Pediatric Heart Conditions
- Cytokinetics price target raised to $52 from $45 at BofA
- Buy Rating Justified for Cytokinetics Due to Aficamten’s Advantages in HCM Treatment
- Cytokinetics price target raised to $80 from $60 at Evercore ISI